Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Leukemia, Myeloid, Acute 2Leukemia 2Congenital Abnormalities 2Small Cell Lung Carcinoma 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Lung Neoplasms 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myelomonocytic, Acute 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Leukemia, Eosinophilic, Acute 1Leukemia, Basophilic, Acute 1

Interventions

Etoposide 78Carboplatin 67Cisplatin 46durvalumab 26Topotecan 26atezolizumab 20Radiotherapy 19Irinotecan 19Paclitaxel 17anlotinib 16apatinib 15Nivolumab 15Drug Therapy 12pembrolizumab 9Platinum 9toripalimab 8tislelizumab 8Gemcitabine 8Bevacizumab 8Temozolomide 7Radiosurgery 7PM 01183 7Ipilimumab 7Pemetrexed 6Docetaxel 6Albumin-Bound Paclitaxel 6olaparib 5amrubicin 5Sunitinib 5surufatinib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Small Cell Lung Carcinoma × laromustine × Clear all
NCT00282022 2013-11-06

VNP40101M in Treating Patients With Relapsed or Refractory Locally Advanced or Metastatic Small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 2 Completed
87 enrolled
Thoracic

Lung Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡